Improved Specificity for Breast Cancer Screening Using an Oncogenic(miRNA-21)and a Gene Suppressor(miRNA-195)miRNA in the Serum for a Point of Care(POC)Screening Solution  

作　　者：Krishnamoorthy Kokilavani Ancy Terryna Chanayiltharayil John Bindu Salim Madhulika Vijayakumar Sankar Ganesh Jeyaraj 

机构地区：[1]PSG Institute of Advanced Studies,Avinashi Road,Peelamedu,Coimbatore,641004 [2]PSG Institute of Medical Science and Research Avinashi Road,Peelamedu,Coimbatore,641004 [3]PSG Center for Molecular Medicine and Therapeutics,PSG Institute of Medical Sciences and Research,Coimbatore,Tamil Nadu,641004,India [4]PSG Centre for Genetics and Molecular Biology,Off Avinashi Road,Peelamedu,Coimbatore,Tamil Nadu,641004,India

出　　处：《Biomedical and Environmental Sciences》2023年第6期549-552,共4页生物医学与环境科学（英文版）

基　　金：Department of science and Technology/Technology Development Program/Biomedical Device and Technology Development,Govt.Of India for the grant allocated for this project。

摘　　要：The overall incidence and burden caused by breast cancer is increasing,affecting the global socio-economic development and life expectancy[1].According to“WHO Global Breast Cancer Initiative(GBCI)reports”,if the mortality rate due to breast cancer can be reduced by 2.4%annually,we may prevent 2.5 million breast cancer deaths between2020-2040.

关 键 词：Breast Cancer SERUM 

分 类 号：R737.9[医药卫生—肿瘤]